| Comprehensive molecular profiling of lung adenocarcinoma Cancer Genome Atlas Research Network Nature 511 (7511), 543, 2014 | 4934* | 2014 |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237, 2018 | 2663* | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2658 | 2017 |
| Nivolumab plus ipilimumab in advanced non–small-cell lung cancer MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ... New England Journal of Medicine 381 (21), 2020-2031, 2019 | 2586 | 2019 |
| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ... New England Journal of Medicine 377 (9), 829-838, 2017 | 2536 | 2017 |
| Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan, ... Annals of oncology 28, iv119-iv142, 2017 | 2378 | 2017 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56, 2019 | 2309 | 2019 |
| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ... Annals of oncology 28, iv1-iv21, 2017 | 1982 | 2017 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1959 | 2020 |
| Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ... Nature reviews Clinical oncology 16 (9), 563-580, 2019 | 1932 | 2019 |
| Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ J Haanen, M Obeid, L Spain, F Carbonnel, Y Wang, C Robert, AR Lyon, ... Annals of Oncology 33 (12), 1217-1238, 2022 | 1080* | 2022 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ... Annals of Oncology 27, v1-v27, 2016 | 1023 | 2016 |
| Brain metastases AS Achrol, RC Rennert, C Anders, R Soffietti, MS Ahluwalia, L Nayak, ... Nature Reviews Disease Primers 5 (1), 5, 2019 | 1011 | 2019 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 1008 | 2021 |
| Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Reck, S Popat, N Reinmuth, D De Ruysscher, KM Kerr, S Peters Annals of oncology 25, iii27-iii39, 2014 | 809 | 2014 |
| Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ... Journal of clinical oncology 31 (16), 1997-2003, 2013 | 781 | 2013 |
| Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Früh, D De Ruysscher, S Popat, L Crinò, S Peters, E Felip Annals of oncology 24, vi99-vi105, 2013 | 720 | 2013 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 688 | 2020 |
| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ... Annals of oncology 24, vi89-vi98, 2013 | 655 | 2013 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369-2379, 2020 | 620 | 2020 |
